AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended ...

Data presentations for the Company’s flagship TTR franchise include new findings from an analysis of the HELIOS-B Phase 3 study of vutrisiran, an RNAi therapeutic in development for the ...

The global vutrisiran market, valued at USD 600 million in 2022, is expected to experience substantial growth, reaching an estimated USD 2,087 million by 2033, with a compound annual growth rate (CAGR ...

Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market. Regulatory risks and competition exist, but ALNY's innovative RNAi platform and ...

Patients may present with polyneuropathy (PN), cardiomyopathy (CM), or both manifestations of disease. Vutrisiran is an RNAi therapeutic that delivers rapid knockdown of mutant and wild?type TTR, ...

Alnylam Pharmaceuticals is expanding the footprint of its RNA-based gene-silencing heart drug, vutrisiran, CEO Yvonne Greenstreet said yesterday during the 2024 STAT Summit in Boston. The drug’s ...

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR ...

− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – CAMBRIDGE, MA, ...